Chad vs Mali: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Chad
2.2%
in 2024
Mali
1.8%
in 2024
Chad rank
11th
Mali rank
14th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Chad
- Mali
How they compare
Chad currently reports 2.2% against 1.8% in Mali, a difference of 0.4%.
That makes Chad's figure about 1.2 times Mali's.
Across all 10 years both countries report, Chad has been ahead every year.
Chad ranks 11th and Mali ranks 14th of 215 countries.
Chad has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Chad | Mali | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4.1% | 2.1% | 2.1% | Chad |
| 2020s | 3.0% | 2.1% | 0.9% | Chad |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Chad or Mali?
- Chad, at 2.2% against 1.8% in Mali as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Chad and Mali?
- 0.4%, with Chad ahead.
- How many years of comparable data are there for Chad and Mali?
- 10 years are reported by both, from 2015 to 2024.
- How do Chad and Mali rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Chad ranks 11th and Mali ranks 14th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.